At University College London Hospitals, researchers tested a weight-loss drug on patients who had undergone surgery but still carried excess weight—and found something that could reshape how doctors treat severe obesity. The BARI-STEP trial, published in Nature Medicine and led by Dr. Janine Makaronidis, offers a lifeline to roughly one in five people who have bariatric surgery but experience little weight loss or regain pounds afterward.
Bariatric surgery—procedures like sleeve gastrectomy and gastric bypass that fundamentally reshape the digestive system—remains one of medicine's most powerful tools for severe obesity. Yet with around 500,000 of these operations performed globally each year, the failure rate creates an enormous clinical challenge. Until now, patients who didn't respond well to surgery faced grim options: lifestyle interventions with limited success, or risky repeat operations available only to a select few.
The trial recruited 70 patients from two London hospitals who took part over 68 weeks, randomly receiving either semaglutide—a medication at 2.4mg—or placebo injections. Both groups also received lifestyle advice and support with reduced-calorie diets. The results were striking. Among those taking semaglutide, 85 percent lost at least 10 percent of their body weight, compared to just 7 percent in the placebo group. Even more impressive: 62 percent of the semaglutide group shed at least 15 percent of body weight, while 47 percent achieved 20 percent or greater weight loss—numbers that dwarf the 7 and 3 percent rates in the placebo arm.
What makes this particularly significant is where the weight came from. Researchers found that most losses were body fat rather than muscle, preserving the lean tissue that keeps people strong and metabolically healthy. The benefits extended beyond the scale. Patients taking semaglutide showed measurable improvements in blood sugar levels, cholesterol, and other markers tied to heart and metabolic health. They also reported better quality of life. The drug's side effects—primarily nausea and reduced appetite—were already well documented from earlier research and largely manageable.
This trial represents the first rigorous randomized controlled test of semaglutide specifically in patients who have failed to respond to bariatric surgery. A similar drug, liraglutide, had shown some benefit in this population, but earlier evidence suggested semaglutide produced greater weight loss. That edge now appears confirmed under controlled conditions.
Dr. Makaronidis framed the implications clearly: these findings make the case for semaglutide as a genuine alternative to repeat operations, and they highlight the potential of combining surgery with weight-loss medicines as a comprehensive approach to severe obesity. The next phase is already in view. Researchers want larger, longer studies with more diverse patient populations. Equally intriguing is the possibility that semaglutide could help patients before surgery, not just after—potentially optimizing outcomes from the start.
For the roughly 100,000 people globally each year for whom bariatric surgery fails, this research opens a door that was firmly closed. It's a reminder that medicine often advances not through a single breakthrough but through the intelligent combination of existing tools, tested rigorously and deployed thoughtfully.